Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients Via Analysis of Immunoinflammation-related Protein Complexes in Blood
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 200
- Locations
- 1
- Primary Endpoint
- blood markers
Overview
Brief Summary
The relationship between immune inflammation-related protein complexes in blood of triple negative breast cancer patients and recurrence or metastasis of breast cancer will be studied.
Detailed Description
200 patients with triple negative breast cancer will be followed up. Peripheral venous blood was collected every 3 to 6 months. Change regularity of breast cancer-specific immune inflammation-related protein complexes in blood at different follow-up time points will be studied. The relationship between disease-specific protein complexes and pathological state of patients will be analyzed.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 36 Years to 60 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Postoperative pathology confirmed invasive breast cancer after surgery for breast lump
- •Breast cancer-related chemotherapy and radiotherapy completed
- •triple negative breast cancer patients
- •age ≤ 60 years old
Exclusion Criteria
- •Aged above 60
- •Breast Carcinoma in situ
- •Women in pregnancy or breastfeeding
- •Suffering from other malignant tumors
- •Non-compliant patient
Outcomes
Primary Outcomes
blood markers
Time Frame: 2 years
The expression of CA153, CEA, CA125 in the blood of the patients, which are measured by electro-chemiluminescence immunoassay.
immune inflammation-related protein complexes
Time Frame: 2 years
The change of immune inflammation-related protein complexes which is measured by gel permeation chromatography.
Secondary Outcomes
No secondary outcomes reported
Investigators
Xi Shen
Attending doctor
Peking Union Medical College Hospital